← Browse by Condition
Medical Condition

inflammatory bowel diseases

Total Trials
11
Recruiting Now
11
Trial Phases
Phase 2, Phase 3, Phase 2
NCT06042387
Recruiting

Genome Analysis Across Populations in Inflammatory Bowel Disease

Enrollment
150 pts
Location
Canada
Sponsor
Mount Sinai Hospital, Canada
View Trial →
NCT03894228
Recruiting

Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry)

Enrollment
1,750 pts
Location
Spain
Sponsor
Grupo Espanol de Trabajo en En...
View Trial →
NCT04280510
Recruiting

Pathogenic Study of Adult Immune Enteropathies

Enrollment
200 pts
Location
France
Sponsor
Institut National de la Santé ...
View Trial →
NCT06512441
Recruiting

Vitamin B6 Aids in Treating Inflammatory Bowel Disease

Enrollment
220 pts
Location
China
Sponsor
Changhai Hospital
View Trial →
NCT06447870
Recruiting

Research on the Mechanisms of Treatment Non-response in Inflammatory Bowel Disease Based on Multi-omics Technology

Enrollment
30 pts
Location
China
Sponsor
Nanfang Hospital, Southern Med...
View Trial →
NCT06550310
Recruiting

Nutrition and Clinical Outcomes in IBD

Enrollment
300 pts
Location
United Kingdom
Sponsor
Barts & The London NHS Trust
View Trial →
NCT06382519
Recruiting

Thalidomide Therapy for VEOIBD

Enrollment
40 pts
Location
China
Sponsor
Children's Hospital of Fudan U...
View Trial →
NCT04995224
Recruiting

Mechanism of Chronic Pain in Patients With IBD

Enrollment
25,600 pts
Location
United Kingdom
Sponsor
Queen Mary University of Londo...
View Trial →
NCT06309017
Recruiting

Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease

Enrollment
150 pts
Location
United States
Sponsor
NYU Langone Health
View Trial →
NCT05986136 Phase 2, Phase 3
Recruiting

Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Enrollment
50 pts
Location
Egypt
Sponsor
Mostafa Bahaa
View Trial →
NCT06453317 Phase 2
Recruiting

Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis

Enrollment
172 pts
Location
Poland
Sponsor
Medical University of Lodz
View Trial →